Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw some unusual options trading on Friday. Traders purchased 32,948 call options on the stock. This represents an increase of approximately 1,371% compared to the typical daily volume of 2,240 call options.
Roivant Sciences Stock Up 2.4 %
Shares of NASDAQ:ROIV traded up $0.26 during midday trading on Friday, reaching $11.15. The company's stock had a trading volume of 3,991,029 shares, compared to its average volume of 4,830,982. The stock has a fifty day moving average of $11.80 and a 200 day moving average of $11.58. Roivant Sciences has a twelve month low of $9.69 and a twelve month high of $13.06. The firm has a market capitalization of $8.12 billion, a PE ratio of 1.97 and a beta of 1.27.
Wall Street Analyst Weigh In
ROIV has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Roivant Sciences currently has an average rating of "Moderate Buy" and an average price target of $17.93.
Read Our Latest Research Report on ROIV
Insider Buying and Selling at Roivant Sciences
In other news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business's stock in a transaction on Monday, January 13th. The shares were acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the sale, the chief operating officer now owns 617,470 shares of the company's stock, valued at approximately $7,193,525.50. This represents a 13.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,942,629 shares of company stock worth $23,071,486 over the last quarter. Insiders own 7.90% of the company's stock.
Hedge Funds Weigh In On Roivant Sciences
A number of institutional investors have recently modified their holdings of ROIV. Acadian Asset Management LLC boosted its stake in shares of Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company's stock worth $89,000 after buying an additional 1,603 shares during the last quarter. American Century Companies Inc. lifted its holdings in Roivant Sciences by 26.5% in the second quarter. American Century Companies Inc. now owns 81,422 shares of the company's stock valued at $861,000 after acquiring an additional 17,074 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Roivant Sciences in the 2nd quarter worth approximately $2,671,000. Mutual of America Capital Management LLC grew its stake in shares of Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company's stock worth $3,457,000 after purchasing an additional 1,142 shares during the period. Finally, E Fund Management Co. Ltd. increased its holdings in shares of Roivant Sciences by 24.2% during the 2nd quarter. E Fund Management Co. Ltd. now owns 50,381 shares of the company's stock valued at $533,000 after purchasing an additional 9,805 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
